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Month YearHigh–bleeding risk (HBR) patients represent up to 45%
of the patients with coronary artery disease (CAD)
undergoing stent implantation, depending on the setting
and bleeding risk definition.1
The European and American guidelines endorse by
consensus the assessment of bleeding risk to inform the
decision making on duration of antiplatelet therapy in
patients undergoing percutaneous coronary intervention
(PCI) and suggest a shorter than average antiplatelet
therapy duration in patients fulfilling at least 1 HBR
criterion.2,3 However, only few studies have so far
focused on HBR patients receiving stent implantation4-9;
no dedicated randomized controlled trial (RCT) has
assessed the optimal antiplatelet therapy regimen in
HBR patients undergoing PCI, whereas pivotal antiplate-
let therapy duration studies have excluded patients with
1 or more HBR criteria.2,3,10 Therefore, the optimal
antiplatelet therapy duration in HBR patients receiving
coronary stenting remains uncertain.HBR and type of coronary stent
The Zotarolimus-Eluting Endeavor sprint stent in
Uncertain DES candidates (ZEUS), which compared any
commercially available thin-strut bare metal stent (BMS)
or Zotarolimus-eluting Endeavor Sprint stent (E-ZES) at
the time of PCI, was the first randomized controlled study
that included, among others, patients with HBR fea-
tures.4-6 It included a total of 1,606 participants, and a
total of 828 patients fulfilled 1 or more HBR criteria, of
whom 425 (51.3%) were aged N80 years, 311 (37.6%) had
clinical indication to oral anticoagulant (OAC), 113
(13.6%) reported previous or recent bleeding requiring
hospitalization or medical attention, 95 (11.5%) present-
ed bleeding diathesis, 68 (8.2%) had known anemia, and
25 (3.0%) were in the need for chronic treatment with
steroids or nonsteroidal anti-inflammatory drugs. In this
selected high-risk patient population, the study protocol
mandated 30-day dual-antiplatelet therapy (DAPT) irre-
spective of the stent type. HBR patients derived benefits
in terms of reductions of major adverse cardiac events
(MACE), myocardial infarction (MI), target vessel revas-
cularization (TVR), and stent thrombosis (ST) when
treated with E-ZES as compared to BMS. More recently,
the Prospective Randomized Comparison of the BioFree-
dom Biolimus A9 Drug-Coated Stent versus the Gazelle
Bare-Metal Stent in Patients at High Bleeding Risk
(LEADERS FREE) trial was designed to evaluate the
efficacy and safety of the polymer-free Biolimus A9–
coated stent as compared with a BMS in HBR patients,
with a 1-month regimen of DAPT in both groups.7,8
Definition of HBR differed from that used in the ZEUS trial
and also included patients who were otherwise consid-
ered by the investigator to be candidates for implantation
of a BMS instead of a drug-eluting stent owing to the
perceived need to terminate DAPT at 1 month. In a totalof 2,466 patients, a polymer-free Biolimus A9–coated
stent was superior to a BMS with respect to the primary
safety and efficacy end points when used with a 1-month
course of DAPT, owing to lower TVR and MI rates.8,11
Finally, 1,200 patients aged 75 years or older have been
included in the short duration of DAPT with Synergy II
Stent in Patients Older Than 75 Years Undergoing
Percutaneous Coronary Revascularization (SENIOR) trial
which compared everolimus-eluting Synergy stent with
BMS followed by 1- or 6-month DAPT duration in stable or
unstable CAD patients, irrespective of the stent type.9 At
12 months, the primary end point—a composite of all-
cause mortality, MI, and ischemia-driven target lesion
revascularization (TLR)—occurred in 16.4% of patients
treated with the BMS and 11.6% among those treated with
Synergy, a 29% relative reduction in risk (RR 0.71; 95% CI
0.52-0.94). There was no statistically significant differ-
ence in the risk of death, stroke, or MI at 12 months, nor
was there any difference in the risk of bleeding, but TLR
was higher with BMS as compared to Synergy.9
Therefore, current evidence4,6,8,9 suggests that BMS
should no longer be considered the device of choice in
HBR patients undergoing PCI even if a relatively short
BMS-like DAPT duration is anticipated. Accordingly, the
European Society of Cardiology DAPT focused update
recommended the use of drug-eluting stent over BMS
irrespective of the planned DAPT duration with a class I
level of evidence A.2
Investigational aspirin-free antithrombotic
regimensafter coronary stent implantation
Multiple studies have so far investigated the safety and
efficacy of dropping aspirin shortly after coronary stent
implantation, mainly in patients who have concomitant
indication to OAC. A recent meta-analysis pooled 4
randomized trials including 5,317 patients assessing the
strategy of DAT versus triple antithrombotic therapy
(TAT) mainly in atrial fibrillation patients following PCI.12
Compared with patients in the TAT arm, patients in the
DAT arm demonstrated a 47% relative reduction in the
risk of Thrombolysis in Myocardial Infarction major or
minor bleeding [4.3% vs 9.0%; HR 0.53, 95% CrI 0.36-
0.85]. There was apparently no difference with respect to
composite or individual ischemic end points. However,
the uncertainty around the point estimates for MI and ST
entailed the possibility that a DAT regimen may still be
associated to 2- or 3-fold higher risk of events as
compared to TAT, respectively.
Moreover, the only study which limited TAT duration
to 6 months and which mandated the use of the same
type of OAC in both study arms did not observe an excess
of bleeding events in the long-term TAT group (ISAR-
TRIPLE). This observation raises the question of whether
a strategy based on few months of TAT followed by a
single antiplatelet therapy in conjunction with an OAC
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and events while offering full ischemic protection shortly
after intervention.
The most recent GLOBAL LEADERS trial is the largest
trial so far testing 1 month of DAPT (aspirin with
ticagrelor) versus standard DAPT after stent implantation.
The trial failed to show a superiority of this new
treatment strategy with respect to the primary end
point of death or new Q-wave MI. Yet, it provided
reassurance over the safety of new tested antiplatelet
regimen. In this study, patients with concomitant
indication to OAC were excluded.13
HBR and DAPT duration
There is no dedicated RCT assessing the optimal DAPT
duration in patients at HBR. Moreover, many, if not all,
available DAPT studies formally excluded these patients.
In a post hoc analysis of the Prolonging Dual
Antiplatelet Treatment After Grading Stent- Induced
Intimal Hyperplasia Study (PRODIGY), it was observed
that patients at HBR according to the CRUSADE score
treated with a 24-month DAPT experienced a 3-fold
higher risk of major bleeding and a 5-fold risk of red blood
cell transfusion as compared with a 6-month therapy,
without clear evidence of benefit.14,15 The number of
patients needed to treat for harm in the HBR group was as
low as 17 and 15 for major bleeding and red blood cell
transfusion, respectively, which was lower than corre-
sponding figures in the unselected patient cohort,
suggesting that long-term DAPT has a narrow therapeutic
window and high potential for harm in this selected HBR
patient population. More recently, it was observed that
among patients deemed at HBR based on PRECISE-DAPT,
prolonged (ie, 12 months or longer) DAPT regimen was
associated with no ischemic benefit but a remarkable
bleeding burden as compared to 3- or 6-month DAPT,
leading to a number needed to treat for harm of 38.16
Conversely, longer treatment duration in patients without
HBR was associated to a marginal or even no increase of
bleeding and a significant reduction of the composite
ischemic end point, with a significant interaction terms
between HBR status according to the PRECISE-DAPT
score and anticipated treatment benefits and risks.16
Ultimaster (TANSEI) stent
The Ultimaster (TANSEI) coronary stent system consists
of a cobalt-chromium BMS platform featuring thin struts
(80 μm).17-19 The Ultimaster (TANSEI) platform is coated
with sirolimus (3.9 μg/mm stent length) in a matrix with
bioresorbable, poly(DL-lactide-co-caprolactone) polymer.
A thin biocompatible, bioresorbable gradient coating is
intended to reduce polymer cracking and delamination
on the hinges of the stent. Within 3 to 4 months, the
polymer is metabolized through the hydrolysis of DL-
lactide and caprolactone into carbon dioxide and water.Because of an abluminal (outside surface) coating, the
dose of drug was reduced as compared to stents coated
both endo- and abluminally. Furthermore, coating only
the abluminal surface leaves the luminal side of the stent
free from drug and polymer, as such enhancing
endothelial coverage.20
The Ultimaster (TANSEI) stent is the only sirolimus-
eluting stent having received CE mark labeling for 1-
month DAPT duration in HBR population. More precisely,
the instruction for use indicates that DAPT after
implantation of Ultimaster (TANSEI) stent can be
discontinued earlier in case of clinical need (ie, HBR)
but not before 1 month.
Methods
Study design and population
The MAnagement of high bleeding risk patients post
bioresorbable polymer coated STEnt implantation with
an abbReviated versus standard DAPT regimen (MASTER
DAPT, clinicaltrial.gov NCT03023020) is an investigator-
initiated, open-label, multicenter, randomized trial com-
paring an abbreviated (experimental arm) versus a
standard (control group) duration of antiplatelet therapy
after bioresorbable polymer-coated Ultimaster or Ulti-
master TANSEI sirolimus-eluting stent implantation re-
gardless of PCI indication in approximately 4,300 HBR
patients recruited from ≥100 interventional cardiology
centers across the globe. After a mandatory 30-day DAPT
run-in phase, patients are randomized to (a) a single
antiplatelet regimen until study completion or up to
5 months in patients with clinically indicated OAC
(experimental 1-month DAPT group) or (b) continue
DAPT for at least 5 months in patients without or for at
least 2 months in patients with concomitant indication to
OAC, followed by a single antiplatelet regimen (standard
antiplatelet regimen) (Figures 1 and 2). Eligible patients
are aged 18 or more, with at least 1 HBR criterion (Table
I) and with all intended coronary lesions successfully
treated with Ultimaster or Ultimaster TANSEI stent
without flow-limiting angiographic complications which
require prolonged prescription of DAPT at operator's
discretion. In addition, all staged PCIs (if any) must be
completed, and no further PCI should be planned.
Detailed inclusion and exclusion criteria are shown in
Table II. No extramural funding was used to support this
work. The authors are solely responsible for the design
and conduct of this study; all study analyses, the drafting
and editing of the paper, and its final contents.
Screening phase
Patients are screened for inclusion from immediately
after the index procedure—defined as either a single
procedure or the last installment in planned staged
procedure—and up to 1-month randomization visit,
occurring between 30 and 44 days thereafter. Consenting
Figure 2
Treatment in the experimental and control arm. In patients randomized to an abbreviated antiplatelet regimenwithoutOAC, a single antiplatelet agent (SAPT;
either ASA or P2Y12i) is continued until 11 months postrandomization. In patients requiring OAC, an SAPT (either ASA or clopidogrel) is continued until
5 months postrandomization, andOAC is prescribed until at least 11 months postrandomization. In patients randomized to a standard antiplatelet regimen
withoutOAC, aspirin is continueduntil at least 11 months postrandomization. The P2Y12 inhibitor being takenat the timeof randomization is continued for at
least 5 months postrandomizationandup to11 months postrandomization. In patients requiringOAC,aspirin and clopidogrel are continued for at 2 months
after randomization and up to 11 months postrandomization. Thereafter, a single antiplatelet (SAPT; either aspirin or clopidogrel) is continued up to
11 monthspost randomization. OAC is continued until at least 11 months postrandomization.
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Table I. HBR criteria
Post-PCI patients are at HBR if at least 1 of the following criteria applies:
1. Clinical indication for treatment with OAC for at least 12 m
2. Recent (b12 m) non–access-site bleeding episode(s), which required medical attention (ie, actionable bleeding)
3. Previous bleeding episode(s) which required hospitalization if the underlying cause has not been definitively treated (ie, surgical removal of the bleeding
source)
4. Age equal or greater 75 y
5. Systemic conditions associated with an increased bleeding risk (eg, hematological disorders, including a history of current thrombocytopenia defined as
a platelet count b100.00/mm3 (b100 × 109/L) or any known coagulation disorder associated with increased bleeding risk
6. Documented anemia defined as repeated hemoglobin levels b11 g/dL or transfusion within 4 wk before inclusion
7. Need for chronic treatment with steroids or nonsteroidal anti-inflammatory drugs
8. Diagnosed malignancy (other than skin) considered at HBR including gastrointestinal, genitourethral/renal, and pulmonary
9. Stroke at any time or TIA in the previous 6 months
10. PRECISE-DAPT score⁎ ≥25
⁎ PRECISE DAPT score is a 5-item bleeding risk score, developed and externally validated to predict the out-of-hospital bleeding risk while on DAPT, which integrates prior bleeding,
age, white blood cell count, creatinine clearance, and hemoglobin.16 Further details about PRECISE DAPT and online calculator can be found at http://www.precisedaptscore.com/
predapt/webcalculator.html.
Table II. Inclusion and exclusion criteria
Inclusion criteria
Inclusion criteria after index PCI
1. Age ≥18 y
2. At least 1 HBR criterion (listed above)
3. All coronary lesions are successfully treated with Ultimaster (TANSEI) stent
4. Free of any flow-limiting angiographic complications which required prolonged DAPT duration based on operator's decision
5. All stages of PCI are complete (if any), and no further PCI is planned
Inclusion criteria at 1-m randomization visit (30-44 d after qualifying index PCI)
1. At least 1 HBR criterion (listed above) or on the basis of post-PCI actionable non–access-site related bleeding episode
2. Uneventful 30-d clinical course (ie, new episode of acute coronary syndrome, symptomatic restenosis, ST, stroke, any revascularization requiring
prolonged DAPT)
3. If not on OAC:
a) Patient is on DAPT regimen of aspirin and a P2Y12 inhibitor;
b) Patient with 1 type of P2Y12 inhibitor for at least 7 d
4. If on OAC:
a) Patient is on the same type of OAC for at least 7 d;
b) Patient is on clopidogrel for at least 7 d
Exclusion criteria
Patients are not eligible if any of the following applies:
1. Treated with stent other than Ultimaster (TANSEI) stent within 6 m prior to index PCI
2. Treated for in-stent restenosis or ST at index PCI or within 6 m before
3. Treated with a bioresorbable scaffold at any time prior to index procedure
4. Incapable of providing written informed consent
5. Under judicial protection, tutorship, or curatorship
6. Unable to understand and follow study-related instructions or unable to comply with study protocol
7. Active bleeding requiring medical attention (BARC ≥2) on randomization visit
8. Life expectancy less than 1 y
9. Known hypersensitivity or allergy for aspirin, clopidogrel, ticagrelor, prasugrel, cobalt-chromium, or sirolimus
10. Any planned and anticipated PCI
11. Participation in another trial
12. Pregnant or breastfeeding women
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and further reassessed for eligibility at the time of
randomization (Figure 1). Patients experiencing sponta-
neous MI, symptomatic restenosis, ST, stroke, or any
revascularization requiring prolonged DAPT after index
PCI will be excluded. Similarly, patients with ongoing
bleeding during the randomization visit are deemed
ineligible. Adherence to only 1 type of DAPT (ie, avoiding
switching among P2Y12 inhibitors) is required for at least7 days prior to randomization. In addition, in patients
with clinically indicated OAC, adherence to 1 type of
OAC (ie, avoiding switching among OACs) and to DAPT
in the form of aspirin and clopidogrel is protocol
mandated for ≥7 days prior to randomization.
Randomization and treatment protocol
At randomization, occurring 30 to 44 days after index
PCI, patients are centrally allocated in a 1:1 ratio to an
Figure 3
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Month Yearabbreviated or standard antiplatelet regimen using
secuTrial data capturing system available at https://
secutrial.insel.ch/apps/WebObjects/ST21-productive-
DataCapture.woa/wa/. The randomization sequence is
computer generated and stratifiedper siteby ahistoryof acute
MI within 12 months prior to index PCI and use of OAC.
Abbreviated antiplatelet regimen. In the experi-
mental arm, the DAPT regimen is immediately discontin-
ued after randomization followed by a single antiplatelet
regimen (either aspirin or P2Y12 inhibitor at discretion of
the treating physician) until study completion or up to
5 months in patients with clinically indicated OAC, which
is continued until at least 11 months postrandomization
(Figure 2).
Standard antiplatelet regimen. In the standard
antiplatelet regimen arm, patientswithout clinically indicated
OAC continue aspirin until 11 months postrandomization
plus a P2Y12i inhibitor (ie, ticagrelor, prasugrel, or
clopidogrel) for at least 5 and up to 11 months postrando-
mization, at the discretionof the treatingphysician (Figure 3).
In patients with clinically indicated OAC, aspirin and
clopidogrel are continued for at least 2 and up to
11 months postrandomization, at the discretion of the
treating physician. Thereafter, a single antiplatelet agent
(aspirin or clopidogrel) is continued up to 11 monthspostrandomization. OAC prescribed before randomiza-
tion is continued until 11 months (Figure 3).
In both study groups, switching among antithrombo-
tics (ie, from one P2Y12 inhibitor to another or among
OACs) is discouraged, unless dictated by a clinical and
documented reason.
All antiplatelet or anticoagulant treatment options are
to be dosed according to the corresponding authorization
for use and locally approved regimens. Daily doses of
allowed antiplatelet regimens include 75-162 mg for
aspirin, 75 mg for clopidogrel, 90 mg for ticagrelor bid,
and 10 mg for prasugrel or 5 mg in patients weighting
b60 kg or who are N75 years old. In Japan, prasugrel is
approved and prescribed at a dose of 3.75 mg.
Daily doses of allowedOACs include apixaban 5 mgbid or
apixaban2.5 mgbid, if at least 2 amongage ≥80 years, body
weight ≤60 kg or serum creatinine level ≥1.5 mg/dL
(or 133 mol/L); dabigatran 150 mg bid or 110 mg bid;
edoxaban 60 mg or 30 mg if creatinine clearance is
30-50 mL/min or body weight ≤60 kg or there is con-
comitant use of verapamil or quinidine or dronedarone;
rivaroxaban 20 mg or 15 mg qd if creatinine clearance
30-49 mL/min.
Finally, the dose intensity of vitamin K antagonist is
monitored with a target international normalized ratio in
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keeping with guideline recommendations.2
Follow-up visits
Scheduled follow-up visits occur at 60 (±14), 150 (±14),
335 (±14), and 420 (±14) days postrandomization. All
follow-up visits are preferably scheduled on-site. If the
patients are unable or unwilling to visit the outpatient
clinic, the scheduled visit can be replaced by telephone
call except for the randomization and the 1-year visits. At
each visit, self-reported adherence to study and nonstudy
medications is collected together with the assessment of
any cardiac or cerebrovascular ischemic or bleeding
occurrences or any serious adverse event.
Study end points
This study has 3 co-primary end points, including (1)
net adverse clinical end points (NACE) defined as the
composite of all-cause death, MI, stroke, and Bleeding
Academic Research Consortium (BARC) 3 or 5 bleeding
events; (2) major adverse cardiac and cerebral events
(MACCE) defined as a composite of all-cause death, MI,
and stroke; and (3) major or clinically relevant
nonmajor bleeding (MCB) defined as a composite of
types 2, 3, and 5 BARC bleeding events.
The secondary end points include the individual
components of the 3 co-primary end points; the
composite of cardiovascular death, MI, and stroke; the
composite of cardiovascular death, MI definite or
probable ST, any revascularization, transient ischemic
attack, and bleeding events adjudicated according to not
only the validated BARC classification21 but also the
Thrombolysis in Myocardial Infarction as well as Global
Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Coronary Arteries (GUSTO)
classifications.
The main analyses evaluate the occurrence of the
primary end points between randomization and
11 months thereafter. Secondary analyses include the
occurrence of primary end points between randomiza-
tion and 15 months and other secondary end points at
any time frames throughout study duration. All primary
and secondary end point definitions are shown in the
supplementary appendix. All primary and secondary end
points are adjudicated by an independent clinical event
committee (CEC) who will be blinded to randomized
treatment allocation.
Statistical considerations
Main analysis of the primary end points is conducted on
the full analysis set of all randomized patients according
to the intention-to-treat principle based on CEC-adjudi-
cated end points.
Rates of primary end points are estimated as the
cumulative incidence from the date of randomization to
335 days (11 months) after randomization by Kaplan-Meier methods. Rate differences are defined as the rate in
the abbreviated antiplatelet minus that in the standard
antiplatelet arms.
The study is designed to test the following hypotheses:
(1) an abbreviated antiplatelet regimen is noninferior to
standard antiplatelet in terms of NACE, (2) an abbreviated
antiplatelet regimen is noninferior to standard antiplatelet
in terms of MACCE, and (3) an abbreviated antiplatelet
regimen is superior to standard antiplatelet in terms of
MCB. These hypotheses are tested in a hierarchical order,
preserving type 1 error rate.
Based on conservative assessments of the previous
evidence,4,6-8,14,15 the event rates of NACE, MACCE, and
MCB in the standard antiplatelet group are assumed to be,
respectively, 12%, 8%, and 6.5% at 1 year.
Noninferiority of the abbreviated antiplatelet regimen
in terms of NACE is declared if the 95% CI of the rate
differences excludes 3.6%. Noninferiority of the abbrevi-
ated DAPT regimen in terms of MACCE is declared if the
95% CI of the rate differences excludes 2.4%.
With 2 × 2,050 evaluable patients, this study has N90%
power to detect noninferiority of abbreviated antiplatelet
for NACE, N80% power to detect noninferiority of
abbreviated antiplatelet on MACE, and N90% to detect
superiority of the abbreviated antiplatelet arm on MCB
assuming a 35% relative risk reduction with nominal 5%
type I error preserved by the sequential hierarchical
testing. To compensate for 5% attrition rate, 2 × 2,150
patients are being randomized.
Predefined subgroup analyses
Prespecified subgroup analyses of the 3 primary and
major secondary end points entail stratification on the
need for OAC at the time of randomization, history of
acute MI within 12 months prior to randomization, acute
coronary syndrome as indication to index PCI, PRECISE-
DAPT or DAPT scores, gender, age, diabetes mellitus, and
the fulfillment of each inclusion criterion.
Study organization, timelines, and conclusions
This study is an investigator-driven clinical trial
sponsored by European Cardiovascular Research Institute
and supported by an unrestricted research grant from
TERUMO Corporation, Tokyo, Japan. The Executive
Committee (ExC) is responsible for scientific content
and oversight of the study and oversees publication. The
Steering Committee is comprised of the ExC and
national/regional lead investigators. The Operational
Committee is responsible for executing and implement-
ing study procedures under the supervision of the ExC.
The Data Monitoring Committee is an independent,
multidisciplinary board composed of 3 members who
are not directly involved in the conduct of the trial and is
responsible for ensuring the safety of the patients
participating in the clinical study. The Data Monitoring
Committee members wil l ser iously consider
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Month Yearrecommending early termination of the trial when the
abbreviated DAPT regimen would show a statistically
significant increased rate of (cardiovascular) mortality or
of MACCE, provided the latter is not counterbalanced by
a reciprocal reduction in the rate of major bleeding. An
independent, multidisciplinary, and blinded CEC is
responsible for the adjudication of all investigator-
reported as well as electronically triggered potential
end points events from the electronic case report form.
Independent study monitoring and site management are
performed by Cardiovascular European Research Center
(Massy, France), Cardialysis (Rotterdam, the Netherlands),
and CV Quest (Tokyo, Japan). Data management, central
data review, and statistical analyses will be conducted by an
independent academic Clinical Trial Unit located in Bern,
Switzerland. The first study patient was randomized in April
2016, and enrolment is projected to reach completion byQ4
2019. At 10th December 2018, 2,196 patients were
randomized, and their distribution according to each HBR
criterion is shown in Figure 3.
MASTER DAPT is the first dedicated randomized
clinical trial aiming at investigating the optimal duration
of antiplatelet therapy in patients with HBR features after
bioresorbable polymer-coated stent implantation.Disclosures
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